Where Will Viking Therapeutics Stock Be in 10 Years?
Saturday, 23 March 2024, 09:53
Viking Therapeutics Projection
Viking Therapeutics is now among the hot biotech stocks as they disclosed encouraging phase 2 results of the VK2735. Without any doubt, discussions with the FDA could fast-track the drug, leading to potential market launch in 2027.
- Potential Growth: Analysts project VK2735 could yield sales of $14.4 billion in the U.S. and $7.2 billion in Europe, significantly boosting Viking's value.
- VK2809 Pipeline: The pipeline evaluation for NASH treatment could be another game-changer for Viking if approved.
Possible Scenarios
- Thriving: Viking's market cap could soar to $130 billion if all goes as planned, with VK2735 leading the way.
- Struggling: Rivals in the obesity and NASH markets pose a threat if they introduce superior therapies.
- Acquisition: Viking may become an appealing target for acquisition by established drugmakers eyeing the obesity and NASH segments.
Investing in Viking Therapeutics currently? Make an informed decision considering potential scenarios and market dynamics.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.